This activity was supported by an educational grant from Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd.
In the spirit of full disclosure and in compliance with all Accreditation Council for Continuing Medical Education (ACCME) Essential Areas and Policies, the faculty for this CME activity were asked to complete a statement regarding all relevant personal financial relationships between themselves or their spouse/partner and any commercial interest occurring within the 12 months prior to joining this activity. The CME Institute has resolved any conflicts of interest that were identified. The disclosures are as follows:
Dr. Fleishhacker is a consultant for Johnson & Johnson, Servier, and Pfizer; has received grant/research support from Eli Lilly, Otsuka, Bristol-Myers Squibb, and Janssen; and has received honoraria from and is a member of the speakers/advisory boards for Pfizer, AstraZeneca, Johnson & Johnson, Eli Lilly, Bristol-Myers Squibb, and Otsuka.
The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The CME Institute of Physicians Postgraduate Press, Inc., designates this educational activity for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
This Brief Report was published in March 2008 and is eligible for 0.75 AMA PRA Category 1 Credit through March 31, 2011. The latest review of this material was February 2008. To obtain credit for this web activity, study the material and complete the CME Posttest and Evaluation as instructed at the end of the activity.
Individuals with schizophrenia experience poor health and increased mortality due to both natural and unnatural causes. Side effects associated with antipsychotic treatment may contribute to increased morbidity and mortality. Although guidelines for monitoring and managing the physical health of patients with schizophrenia exist, they are not routinely implemented. This activity was designed to meet the needs of participants in CME activities provided by the CME Institute of Physicians Postgraduate Press, Inc., who have requested information on physical health issues in patients with schizophrenia being treated with atypical antipsychotics. There are no prerequisites for participating in this activity.
Disclosure of off-label usage: Dr. Fleischhacker has determined that, to the best of his knowledge, no investigational information about pharmaceutical agents that is outside U.S. Food and Drug Administration-approved labeling has been presented in this activity.
This activity has undergone a 3-tier review process: (1) the entire faculty of the series discussed the content at a peer-review planning session; (2) the Chair reviewed the activity for accuracy and fair balance; and (3) a member of the External CME Advisory Board reviewed the activity to determine whether the material is evidence-based and objective.
This Brief Report was developed from a satellite symposium held during the 20th annual European College of Neuropsychopharmacology (ECNP) Congress, which was held October 13–17, 2007, in Vienna, Austria. This activity was independently developed by the CME Institute of Physicians Postgraduate Press, Inc., in conjunction with the ECNP, pursuant to an educational grant from Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. The opinions expressed herein are those of the faculty and do not necessarily reflect the opinions of the CME provider and publisher or the commercial supporter.
 |
|
| Project Associate | Ariel A. Britton, MA |
| Electronic Media Manager | F. Grant Whittle, PhD |
| Managing Director | Jane B. Eckstein, MA |
| Associate CME Director | Jennifer G. Alessi, MA |
| Assistant CME Director | Susan K. Beaton, BS |
| CME Editor | Becky Brown Derych, MA |
| CME Coordinator | Diane Brunner |
| External CME Advisory Board | |
Chair Michael H. Ebert, MD Vice Chair Richard C. Shelton, MD |
|
E. Sherwood Brown, PhD, MD Stephanie Cavanaugh, MD Lawrence J. Cohen, PharmD Larry Culpepper, MD, MPH John M. Downs, MD Alan J. Gelenberg, MD |
Paul King, MD Joseph A. Lieberman, III, MD Elizabeth H. B. Lin, MD Frank W. Ling, MD J. Sloan Manning, MD Meir Steiner, MD, PhD |
© 2007 Physicians Postgraduate Press, Inc. |
|
Psychiatrist.com Home
Keyword Search